Table 1.
Baseline characteristics of study participants.
| Characteristic | Healthy subjects | Patients with chronic kidney disease | |
|---|---|---|---|
| Colonic dialysis | No dialysis | ||
| N | 34 | 25 | 25 |
| Age (year) | 52.62 ± 6.68 | 56.24 ± 11.7 | 51.08 ± 8.58 |
| Male | 16 (47.1) | 12 (48) | 13(52) |
| SBP (mmHg) | 119.63 ± 18.69 | 138.72 ± 17.37* | 136.04 ± 17.92# |
| DBP (mmHg) | 77.50 ± 12.00 | 81.96 ± 9.01 | 79.32 ± 10.08 |
| CKD stage | |||
| 3–4 (eGFR 15–59) | 0 | 10 | 13 |
| 5 (eGFR < 15) | 0 | 15 | 12 |
| Primary disease | |||
| CGN | 0 | 9 | 16 |
| DM | 0 | 5 | 6 |
| HT | 0 | 7 | 0 |
| SLE | 0 | 1 | 0 |
| AP | 0 | 1 | 0 |
| DPKD | 0 | 0 | 1 |
| Other | 0 | 2 | 2 |
| Colonic dialysis duration (year) | – | 3.26 ± 2.52(0.6–8.5) | – |
| Colonic dialysis frequency (times per week) | – | 3.33 ± 1.39(1–7) | – |
| Laboratory parameters | |||
| Hb (g/L) | 141.97 ± 14.35 | 107.75 ± 20.87* | 96.92 ± 25.50# |
| ALB(g/L) | 46.06 ± 2.50 | 39.67 ± 5.59* | 38.94 ± 8.00# |
| LDL (mmol/L) | 3.29 ± 0.69 | 3.00 ± 0.76 | 3.16 ± 0.77 |
| TG (mmol/L) | 1.57 ± 0.90 | 2.30 ± 1.38* | 2.19 ± 1.45# |
| TC (mmol/L) | 5.27 ± 0.90 | 4.74 ± 1.18 | 5.06 ± 1.03 |
| Glu (mmol/L) | 5.98 ± 1.86 | 5.46 ± 1.29 | 6.36 ± 3.61 |
| Urea (mmol/L) | 5.29 ± 1.32 | 17.11 ± 6.93 | 16.37 ± 6.74 |
| UA (mmol/L) | 334.01 ± 80.22 | 431.18 ± 104.95* | 443.14 ± 103.85# |
| K (mmol/L) | – | 4.52 ± 0.60 | 4.64 ± 0.71 |
| Ca (mmol/L) | – | 2.21 ± 0.15 | 2.20 ± 0.19 |
| P (mmol/L) | – | 1.41 ± 0.30 | 1.46 ± 0.50 |
| Mg (mmol/L) | – | 0.86 ± 0.15 | 0.84 ± 0.10 |
| Qualitative determination of urinary protein | |||
| Negative | 30 | 1 | 1 |
| Microscale | 3 | 3 | 0 |
| Positive | 1 | 21 | 24 |
| Medications at baseline | |||
| Calcium channel-blockers | – | 17 | 11 |
| ACE inhibitors/ARBs | – | 8 | 9 |
| Beta-blockers | – | 10 | 7 |
| Diuretics | – | 2 | 2 |
| Iron agents | – | 3 | 5 |
| Phosphate binders | – | 0 | 0 |
| EPO | – | 5 | 7 |
| Anticoagulants | – | 7 | 6 |
| Lipid-lowering drugs | – | 6 | 5 |
| Antidiabetic drugs | – | 4 | 4 |
| Other BP-lowering drugs | – | 6 | 1 |
Values are n, n (%), or mean ± SD, unless otherwise noted.
SBP systolic blood pressure, DPB diastolic blood pressure, CKD chronic kidney disease, CGN chronic glomerulonephritis, DM diabetic mellitus, HT hypertension, SLE systemic lupus erythematosus, AP allergic purpura, PKD polycystic kidney disease, Hb hemoglobin, ALB albumin, LDL low density lipop-rotein, TG triglyceride, TC cholesterol, Glu glucose, UA uric acid, K potassium, Ca calcium, P phosphorus, Mg magnesium, EPO Erythropoietin. *p < 0.05 versus healthy subjects, #p < 0.05 versus healthy subjects.